natgillin/translations-raw huggingface dataset:
At RT 2.0 ml diethylamine are added and stirring continued for 4 hours at RT. 
Na RT se doda 2,0 ml dietilamina i nastavi se s miješanjem tijekom 4 sata na RT.
The seasonal thermal energy storage system for cold and heat supply of claim 8, characterized in that temperature sensors and liquid level detectors are disposed in the heat source storage pond, the cold source storage pond, the hot water supply pool, and the cold water supply pool; and all the water pumps are provided with a magnetic valve. The seasonal thermal energy storage system for cold and heat supply of claim 9, characterized in that the system further comprises an intelligent control unit, the intelligent control unit is connected to the temperature sensors, the liquid level detectors, and the magnetic valve for controlling the opening/closing of the magnetic valve according to signals gathered by the temperature sensors and the liquid level detectors whereby opening/closing corresponding water pumps. 
Sustav sezonske pohrane toplinske energije za dovođenje rashladnog i toplinskog učina prema zahtjevu 4, naznačen time što su temperaturni senzori i detektori razine tekućine smješteni u bazenu za pohranjivanje izvora topline (11), bazenu za pohranjivanje rashladnog izvora (12), bazenu za opskrbu toplom vodom (41), te bazenu za opskrbu hladnom vodom (42); sve vodene crpke imaju magnetski ventil; inteligentna upravljačka jedinica spojena je na temperaturne senzore, detektore razine tekućine, te magnetski ventil za kontrolu otvaranja/zatvaranja magnetskog ventila prema signalima koje prikupljaju temperaturni senzori i detektori razine tekućine pri čemu se otvaraju/zatvaraju odgovarajuće vodene crpke.
adding an aqueous solution of a mineral acid, such as hydrochloric acid for example 
dodavanje vodene otopine mineralne kiseline, čime se dobiva spoj s formulom (6b):
A compound of formula (II) or a pharmaceutically acceptable salt thereof for use in the treatment of bipolar disorder. 
(U) ili njegova farmaceutski prihvatljiva sol naznačen time da je za upotrebu kod liječenja bipolarnog poremećaja, Spoj formule (IT)
The pharmaceutical formulation of the present invention is one that is suitable for administration of the peptides by any acceptable route such as oral (enteral), nasal, ophthalmic, subcutaneous, intradermal, intramuscular, intravenous or transdermal. 
Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva namijenjen intravenoznoj, intra-arterijskoj, intraperitonalnoj, intramuskularnoj, intradermalnoj, intratumorskoj, oralnoj, dermalnoj, nazalnoj, bukalnoj, rektalnoj, vaginalnoj, inhalacijskoj ili topijskoj primjeni.
The method of claim 1, where the crystalline hydrochloride salt is characterized by a differential scanning calorimetry trace which has a melting point of about 196.9° C. 
Spoj sukladno patentnom zahtjevu 1, naznačen time, da mu je točka taljenja traga diferencijalne pretražne kalorimetrije oko 196.9?C.
A compound according to Formula (Ia): wherein: 
Spoj prema Formuli (Ia): pri čemu:
The system of 1, wherein the indicator is configured to alert the operator when the replaceable portion has been installed for a predetermined period of time. The system of 1, wherein the indicator provides a visual or auditory alert to the operator. 
Sustav u skladu s patentnim zahtjevom 1, naznačen time što je indikator (414), konfiguriran za upozoravanje operatora kada je zamjenjivi dio instaliran u zadanom vremenskom periodu, te što indikator (414) daje vidljivo ili čujno upozorenje operatoru.
the IgG molecule specifically binding IL-4 comprises a variable light chain comprising SEQ ID NO:3 and a variable heavy chain comprising SEQ ID NO:4 or comprises a variable light chain comprising SEQ ID NO:3 and a variable heavy chain comprising SEQ ID NO:5. The bispecific antibody or antibody fragment thereof according to claim 1 or 2, further characterized by one or more of the following features a)-c): 
Izolirano protutijelo ili njegov fragment protutijela koji se specifično veže na IL-4, naznačeno time da protutijelo ili njegov fragment protutijela je humaniziran, te pri čemu protutijelo ili njegov fragment protutijela sadrži varijabilni lagani lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 3 i sadrži varijabilni teški lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 4.
Stability of Active Ingredient 
Stabilnost aktivnog sastojka
Device as claimed in claims 1 - 3 characterised in that said hydraulic unit (24) comprises pumping means suitable for conveying the solution contained in said first tank (23) into the subcutaneous area of the patient through said measuring cell (20). 
Uređaj prema patentnim zahtjevima 1 - 3, naznačen time što navedena hidraulična jedinica (24) sadrži sredstvo za pumpanje pogodno za prijenos otopine sadržane u navedenom prvom rezervoaru (23) u subkutano područje pacijenta pomoću navedene stanice (20) za mjerenje.
an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises: 
protutijelo, ili njegov fragment, izravno ili posredno kovalentno spojen s navedenim konjugatom, gdje navedeni njegov fragment može reagirati s istim antigenom kao odgovarajuće protutijelo, gdje navedeni konjugat sadrži:
Purification of the resulting crude by chromatography on silica eluting firstly with neat ethyl acetate followed by DCM/MeOH (10:1) yields the titled compound as a yellow powder. 
Čišćenjem dobivenog sirovog proizvoda kromatografijom na silika gelu ispirući najprije sa čistim ctil acetatom i zatim s DCM/McOH (10:1) dobije se naslovni spoj kao žuti prah.
A portion of the tablets was provided with a coating as described in Example 1. 
Dio tableta obložen je filmom kako je opisano u Primjeru 1.
The IL-17 antagonist for use according to Claim 4, wherein the first treatment period ends within 30 days after disappearance of all symptoms of the AOID. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 4, naznačen time, da prvo razdoblje liječenja završava unutar 30 dana nakon nestanka svih simptoma AOID.
wC=weight of caramel initially added Colour Intensity For the purpose of this specification, Colour Intensity of a certain material is defined as the absorbance of an 0.1% (w/v) solution of solids in water in a 1 cm quartz cell at 610 nm. 
WC = masa početno dodane karamele Intenzitet boje Za svrhu ove specifikacije, intenzitet boje određenog materijala se definira kao apsorbancija 0,1%-tne (mas/v) otopine čvrste tvari u vodi u 1 cm kvarcnoj ćeliji pri 610 nm.
Hybrid yarn according to claim 1, characterised in that fusible fibres are mixed into the electrically conductive fibres (5). 
Hibridna pređa u skladu s patentnim zahtjevom 1, naznačena time što su topljiva vlakna umiješana u električno vodljiva vlakna (5).
After this, the sheets 6 and 7 are laminated together at a higher temperature, whereby the end result is the data sheet shown in Figure 3. 
Nakon toga, listovi 6 i 7 se zajedno spajaju na višoj temperaturi kao slojevi, pri čemu je krajnji rezultat list za podatke koji je prikazan na slici 3.
The Schild linear plot is generated from the dose-ratios obtained in four independent experiments by linear regression, and the X-intercept is used to determine the affinity of the antagonist. 
Iz odnosa doza za četiri neovisna eksperimenta linearnom je regresijom dobiven Schildov linearni graf, a odsječak na osi x uzet je za određivanje afiniteta antagonista.
BACKGROUND OF THE INVENTION B-adrenergic agonists, in particular B2-adrenergic agonists, and antimuscarinic agents, in particular antagonists of M3 muscarinic receptors, are two classes of bronchodilating drugs useful in the treatment of respiratory disorders, such as asthma or Chronic Obstructive Respiratory Diseases (COPD). 
Kortikosteroidi i antimuškarinski lijekovi, osobito antagonisti M3 muskarinskih receptora, predstavljaju dva razreda lijekova koji su korisni u liječenju respiratornih poremećaja, poput astme ili kronične opstruktivne plućne bolesti (KOPD). lako kortikosteroidi i antimuskarinski lijekovi mogu predstavljati učinkovite terapije, postoji klinička potreba za terapijama u liječenju astme i KOPD s potentnim i selektivnim djelovanjem i povoljnim profilom djelovanja.
In another embodiment, the MASP-3 inhibitory agent binds to a portion of MASP-3 (SEQ ID ON:8) and also binds to a portion of MASP-1 (SEQ ID NO:10), with the proviso that the inhibitory agent does not bind to MASP-2 (SEQ ID NO:5), or MAp19 (SEQ ID NO:3). 
Pripravak koji sadrži količinu sredstva za inhibiranje MASP-3 koja djelotvorno inhibira aktiviranje komplementa ovisno o MASP-3, naznačen time što je namijenjen upotrebi u liječenju subjekta koji boluje od paroksizmalne noćne hemoglobinurije (PNH), gdje je navedeno sredstvo za inhibiranje MASP-3 monoklonsko protutijelo protiv MASP-3, ili njegov fragment, koje se specifično veže na dio ljudskog MASP-3 (SEQ ID NO:8).
The process of claim 11 further comprising coupling an amino-terminal protected Asp residue having a protected carboxyl side chain to a Trp-Pro dipeptide through the Trp residue of the dipeptide and removing the amino-terminal protecting group from the Asp residue to form the 4-6 eptifibatide fragment. 
Postupak prema patentnom zahtjevu 11, naznačen time, da nadalje sadrži kopuliranje amino-terminalno zaštićenog Asp ostatka koji ima zaštićeni karboksilni postrani lanac na Trp-Pro dipeptid preko Trp ostatka dipeptida i uklanjanje amino-terminalne zaštitne skupine iz Asp ostatka da nastane fragment 4-6 eptifibatida.
The pharmaceutical composition according to claim 10 wherein the additional active agent is selected from formoterol, salmeterol, budesonide, and mometasone, in free or pharmaceutically acceptable salt form. 
Farmaceutski pripravak za primjenu prema zahtjevu 8, naznačen time, što je dodatna aktivna tvar odabrana iz formoterola, salmeterola, budezonida i flutikazon propionata, u slobodnom obliku ili u obliku farmaceutski prihvatljive soli.
A solution of Formula 43 (2.1 g, 2.52 mmol) in DCM (10.5 mL) was stirred at room temperature. 
Formula 44 Otopina formule 43 (2.1 g, 2.52 mmol) u DCM (10.5 mL) bila je miješana na sobnoj temperaturi.
The starting amount of methylthioninium chloride hydrates in the process variants a), b) or c) according to the invention may range from 0.1 to 60% by weight, preferably 1 to 50% by weight and more preferably 5 to 40% by weight, based on the total weight of the suspension or solution. 
Postupak prema bilo kojem od zahtjeva 1 do 6, naznačen time, da sadržaj vode u tekućoj fazi ne premašuje 50 masenih %, još bolje 20 masenih %, na osnovi ukupne mase tekuće faze.
The PET container of claim 3 wherein the moisture content of the wall is from about 1780 ppm to about 1980 ppm when exposed to 100% RH at about 96° C. 
PET posuda iz patentnog zahtjeva 1 gdje sadržaj vlage zida je od 1780 ppm do 1980 ppm kada je izložena relativnoj vlažnosti od 100% na 96? C.
In order to do so the control means can monitor the current status of the beverage production device, in order to decide which of the at least two thermoblocks is not about to be used and can thus can be used for supplying hot water to the hot water outlet. 
Kako bi se to izvelo, sustav za kontrolu može pratiti trenutno stanje naprave za proizvodnju napitaka kako bi se odredilo koji od najmanje dva termobloka neće biti u upotrebi, te ga se prema tome može upotrijebiti za dovodenje vruće vode na izlaz za vruću vodu.
cleaving the PEG and linker from the Fab'-PEG with an enzyme that cleaves the hinge portion of the Fab' and releases the PEG and linker from the Fab', 
cijepanje PEG i linkera iz Fab'-PEG s enzimom koji cijepa spojnog dijela Fab' i otpušta PEG i linker iz Fab',
Pharmaceutical compositions containing as the active ingredient a compound as claimed in claims 1 to 6 together with pharmaceutically acceptable excipients. 
Farmaceutski pripravci, naznačeni time da sadrže aktivnu tvar kako je prijavljena u patentnim zahtjevima 1 do 6 skupa s farmaceutski prihvatljivim ekcipijensom.
insoluble whey protein particles having a particle size in the range of 1-10 micron, where the amount of said insoluble whey protein particles is in the range of 50-90% (w/w) relative to the total amount of protein. 
- netopljive čestice proteina sirutke veličine čestica u rasponu od 1-10 um, gdje je količina navedenih netopljivih čestica proteina sirutke u rasponu od 50-90 % (tež./tež.) u odnosu na ukupnu količinu proteina.
the mouse lacks an endogenous mouse k immunoglobulin light chain variable region locus that is capable of rearranging and forming a gene that encodes a mouse k variable region; 
(a) mišu nedostaje lokus varijabilne regije lakog lanca endogenog mišjeg imunoglobulina koji preuređenjem može tvoriti gen koji kodira varijabilnu regiju x miša;
The fuel feedstock of claim 1, further comprising an sorbent for NOx reduction, optionally wherein the sorbent for NOx reduction is urea, optionally wherein the urea comprises 1% (w/w) to 3% (w/w) of the fuel feedstock, or the fuel feedstock of claim 1, further comprising a mercury sorbent and an NOx sorbent, optionally wherein the mercury sorbent is calcium bromide and the NOx sorbent is urea. 
Sirovina za gorivo u skladu s patentnim zahtjevom 1, naznačena time, da nadalje sadržava sorbens za redukciju NOx, po izboru pri čemu je sorbens za redukciju NOx urea, pri čemu po izboru urea sadržava 1 % do 3 % težinskog udjela sirovine za gorivo ili sirovina za gorivo u skladu s patentnim zahtjevom 1, pri čemu dodatno sadržava sorbens za živu i sorbens za NOx, pri čemu je po izboru sorbens za živu kalcijev bromid, a sorbens za NOx je urea.
The granules may include a layer of magnesium oxide coated on the citric acid. According to a further aspect of the invention, there is provided a composition comprising granules including citric acid and magnesium oxide, the granules comprising a layer of magnesium oxide coated on a core of citric acid. 
Farmaceutski pripravak naznačen time da sadrži (a) granule koje obuhvaćaju limunsku kiselinu i magnezijev oksid, te granule sadrže sloj magnezijevog oksida presvučen na jezgru limunske kiseline; i (b) granule koje sadrže natrijev pikosulfat i kalijev bikarbonat, te granule sadrže sloj natrijevog pikosulfata obložen na jezgru od kalijevog bikarbonata.
A compound or use of claim 11, wherein the disorder is selected from the group consisting of mild to moderate dementia of the Alzheimer's type, attention deficit disorder, mild cognitive impairment and age associated memory impairment. 
Spoj, kompozicija ili upotreba prema zahtjevu 6, gdje se poremećaj bira iz skupine koju čine blaga do umjerena demencija Alzheimerovog tipa, blaga kognitivna neusaglašenost i neusaglašenost memorije uslijed starenja.
The aqueous portion is adjusted to pH = 1.9 - 2.1 with 4 M HCl while maintaining the temperature at 20 - 25 °C. The aqueous portion is extracted with isopropyl acetate. 
Vodeni dio podesi se na pH = 1,9 do 2,1 s 4 M HC], uz održavanje temperatura na 20 do 25 *C. Vodeni dio ekstrahira se izopropil-acetatom.
Pharmaceutical composition according to claim 15, characterized in that the at least one pharmaceutically active component is selected from the group consisting of peptides, proteins, nucleic acids, (therapeutically active) low molecular weight organic or inorganic compounds having a molecular weight less than 5000, sugars, antigens, antibodies, pathogens, attenuated pathogens, de-activated pathogens, (human) cells, cellular fragments or fractions and other therapeutic agents, which are preferably adapted to exhibit enhanced transfection properties, including by complexation with lipids and/or polycationic compounds, including polycationis peptides. 
Farmaceutski pripravak prema zahtjevu 3, naznačen time da dodatno sadrži barem jednu farmaceutski aktivnu komponentu poželjno odabranu iz skupine koju čine peptidi, proteini, nukleinske kiseline, (terapijski aktivni) organski ili anorganski spojevi niske molekularne težine koji imaju molekularnu težinu manju od 5000, šećeri, antigeni, protutijela, patogeni, oslabljeni patogeni, deaktivirani patogeni, (ljudske) stanice, stanični fragmenti ili frakcije i druga terapijska sredstva, koja su poželjno prilagođena da imaju poboljšana svojstva transfekcije, uključujući kompleksiranje s lipidima i/ili polikationskim spojevima, uključujući polikationske peptide.
n is an integer ranging from 0 to 2; 
n je cijeli broj od 0 do 2;
An apparatus for bonding the outer shell and inner cup to form an insulated container for hot liquids comprises such a first member to be arranged within the cup body, such second member generally concentric with said first member and arranged outside the outer shell, and at least one radially protruding or movable pressing member to press the opposed shell and cup walls together to form one or more bonding spots and/or bonding areas along the circumference of the shell and the cup body. 
Odgovarajući uređaj za spajanje vanjske ljuske i unutarnje čaše, koji omogućava izradu izoliranog spremnika za vruće tekućine ili nešto slično, ima takav prvi element koji treba biti postavljen s unutarnje strane čaše i takav drugi element koji je uglavnom koncentričan s prvim elementom i postavljen je s vanjske strane vanjske ljuske, i najmanje jedan radijalno izbočeni ili radijalno pomični tlačni element koji pritišće zajedno sa suprotnih strana ljusku i stijenke čaše, da
Hydrating the product of step a) with an aqueous hydration solvent so as to form liposomes 
hidratiranja produkta iz koraka a) s vodenim hidratacijskim otapalom kako bi se dobilo liposome
A method for preventing the recurrence of HCV infection in a transplant recipient in need thereof, comprising administering to said recipient a therapeutically effective amount of a cyclosporin according to claim 1. 
Uporaba ciklosporina u skladu sa zahtjevom 1, naznačena time, da se koristi za pripravu farmaceutskog pripravka za prevenciju ponavljanja HCV infekcije kod primatelja transplatanta.
The substance may be isolated from its enantiomer or synthetized de novo. A second aspect of the present invention provides a method of treating psychological and psychiatric symptoms in a subject having a NE receptor. The method includes administering a substance (such as d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, pharmaceutically acceptable salts thereof, or mixtures thereof) to a subject under conditions effective for the substance to bind to the NE receptor of the subject and thereby relieve the subject from psychological symptoms such as depression, anxiety, fatigue, mood instability including pseudo-bulbar affect. 
HR P20181481 T1 PATENTNI ZAHTJEVI Tvar koja je izabrana iz skupine koja se sastoji od d-metadona, d-metadola, d-alfa-acetilmetadola, d-alfa- normetadola, I-alfa-normetadola, njihovih farmaceutski prihvatljivih soli, i njihovih smjesa za uporabu u liječenju psiholoških i psihijatrijskih simptoma kod subjekta, pri čemu psihološki simptomi uključuju depresiju, anksioznost, umor, i/ili nestabilnost raspoloženja, uključujući pseudo-bulbarni utjecaj; pri čemu je tvar izolirana iz njegovog enantiomera ili sintetizirana de novo; i pri čemu se tvar može vezati na: receptor NMDA (N-metil-D-aspartat) subjekta i/ili receptor NE (norepinefrin) subjekta.
iv) 0.2-0.5 % by weight of magnesium stearate and 0.05-0.2 % by weight of silicon dioxide; and 
1i) sredstvo za kontrolu učestalosti od 3 do 6% po masi; ili) vezivno sredstvo od 35 do 65% po masi.
An isolated nucleic acid molecule encoding at least one isolated IL-23p19 antibody according to any of claims 1-3. 
Izolirana molekula nukleinske kiseline: (a) kodira najmanje jedno izolirano IL-23p19 antitijelo prema patentnom zahtjevu 1 ili patentnom zahtjevu 2;
Nucleic acid molecule encoding a peptide according to claim 1. Vector comprising a nucleic acid molecule according to claim 2. 
Molekula nukleinske kiseline, naznačena time, da kodira peptid prema zahtjevu 4 ili fuzijski protein prema zahtjevu 5 ili 6.
In a preferred embodiment of the pharmaceutical composition according to the invention, the adjuvant is imiquimod or resimiquimod. 
Farmaceutski sastav prema zahtjevu 7, gdje je stanica koja predstavlja antigen dendritična stanica.
wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; wherein each nucleoside of each wing segment comprises a constrained ethyl nucleoside; wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; and wherein each cytosine of the modified oligonucleotide is a 5-methylcytosine. 
pri čemu je segment razmaka smješten između 5' krilnog segmenta i 3' krilnog segmenta; pri čemu svaki nukleozid svakog krilnog segmenta sadrži ograničeni etilni nukleozid; pri čemu svaka internukleozidna veza modificiranog oligonukleotida je fosforotioatna veza; i pri čemu svaki citozin modificiranog oligonukleotida je 5-metilcitozin.
To a suspension of compound 13 (50 mg, 0.19 mmol) in dichloromethane (2 mL) at room temperature was added pyridine (23 µL, 0.28 mmol) followed by isoxazole-5-carbonyl chloride (25 mg, 0.19 mmol). 
Kira U suspenziju spoja 13 (50 mg, 0,19 mmol) u diklormetanu (2 mL) na sobnoj temperaturi doda se piridin (23 uL, 0,28 mmol) nakon čega slijedi izoksazol-5-karbonil klorid (25 mg, 0,19 mmol).
a LDPC decoder configured to LDPC-decode the Layer 1 signaling data and the de-punctured LDPC parity bit; and 
LDPC dekoder (1304a) podešen za LDPC-dekodiranje signalnih podataka Razine 1 i zatvorenih LDPC paritetnih bitova; i
The cellulose reactive glyoxalated copolymer composition according to any one of claims 1-5, wherein the cationic copolymer comprises 20 to 40 weight % diallyldimethylammonium halide monomer and 80 to 60 weight % acrylamide monomer, and has a weight average molecular weight of 150,000 to 400,000 Daltons. 
Sastav glioksaliranog kopolimera reaktivnog sa celulozom prema bilo kojem od zahtjeva 1-5, gdje kationski kopolimer sadrži 20 do 40 masena % dialildimetilamonij halid monomera i 80 do 60 masena % akrilamid monomera, te ima maseni prosjek molekulske mase od 150,000 do 400,000 Daltona.
In certain embodiments, a therapeutically effective amount of the a adrenergic receptor agonist is administered. In certain embodiments, the a adrenergic receptor agonist is administered topically or locally to the patient. In embodiments of the present invention, the a adrenergic agonist may be selected from oxymetazoline, naphazoline, tetrahydrozoline, phenylephrine, xylometazoline, methoxamine, metaraminol, midodrine, desglymidodrine, cirazoline, amidephrine, brimonidine, clonidine, guanfacine, guanabenz, apraclonidine, xylazine, medetomidine, dexmedetomidine, a-methyldopa, and combinations thereof. 
Agonist za uporabu u skladu sa zahtjevom 1, naznačen time što je agonist alfa adrenergijskog receptora odabran od oksimetazolina, nafazolina, tetrahidrozolina, fenilefrina, ksilometazolina, metoksamina, metaraminola, midodrina, desglimidodrina, cirazolina, amidefrina, brimonidina, klonidina, gvanfacina, gvanabenza, apraklonidina, ksilazina, medetomidina, deksmedetomidina, alfa-metildopa, epinefrina, norepinefrina, izoproterenola, dipivefrina, pseudoefedrina, mefentermina, fenilpropanolamina, propilheksedrina, amfetamina, dekstroamfetamina, efedrina, epinina, etilnorepinefrina, levarterenola, lofeksidina, metamfetamina, alfa-metilnorepinefrina, metilfenidata, mivazerola, moksonidina, norepinefrina, norfenilefrina, pemolina, tizanidina i njihovih kombinacija.
In a further embodiment, the immunogenic composition of the invention comprises a Hib saccharide conjugate and at least two N. meningitidis polysaccharide conjugates wherein the Hib conjugate is present in a lower saccharide dose than the mean saccharide dose of the at least two N. meningitidis polysaccharide conjugates. 
Imunogeni pripravak, naznačen time što sadrži konjugat saharida Hib i najmanje dva dodatna konjugata bakterijskih saharida, gdje konjugat Hib je prisutan u manjoj dozi saharida od srednje doze saharida za sve od najmanje dva dodatna konjugata bakterijskih saharida.